Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluating Immune Response to Percutaneous Hepatic Perfusion With Melphalan for the Treatment of Ocular Melanoma Metastatic to the Liver

NCT07364474 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT07364474
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07364474 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluating Immune Response to Percutaneous Hepatic Perfusion With Melphalan for the Treatment of Ocular Melanoma Metastatic to the Liver
Lead sponsor
Massachusetts General Hospital
Phase
Not applicable
Overall status
Recruiting
Start date
January 27, 2026
Completion date
September 30, 2028
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

uveal melanoma